Sign in

    Laura Engel

    Senior Research Analyst at Stonegate Capital Partners

    Laura Engel is a Senior Research Analyst at Stonegate Capital Partners, specializing in equity research for small and mid-cap publicly traded companies, particularly within biotechnology, healthcare, and financial services. She has covered companies including Sonoma Pharmaceuticals, PharmaCyte Biotech, Arlington Asset Investment Corp, and Immunovaccine, offering in-depth valuation analysis and investment recommendations. Engel began her career in public accounting at Arthur Andersen after graduating from the University of Virginia’s McIntire School of Business, subsequently transitioning through corporate finance and consulting roles at KPMG before joining Stonegate in 2003, where she has held various responsibilities since. She is a licensed CPA, leveraging her extensive financial expertise to deliver high-quality research for institutional investors.

    Laura Engel's questions to Sonoma Pharmaceuticals (SNOA) leadership

    Laura Engel's questions to Sonoma Pharmaceuticals (SNOA) leadership • Q1 2019

    Question

    Laura Engel from Stonegate Capital Partners asked about the impact of the ongoing Invekra deal on margins, margin expectations for the rest of the fiscal year, and the long-term potential and associated costs of the new mail-order program.

    Answer

    CEO James Schutz explained that while Latin America margins are in the mid-high teens, overall margins are expected to rise to the high 60% to low 70% range as the high-margin dermatology business grows. He and CFO Robert Miller projected the mail-order channel could account for 60% of U.S. prescriptions by year-end, which would narrow the gross-to-net revenue gap by reducing rebate costs and leveraging lower service fees compared to traditional wholesalers.

    Ask Fintool Equity Research AI